Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a report published on Friday morning. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $2.00 target price on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Price Performance

Shares of NYSE SENS opened at $0.41 on Friday. The stock has a market capitalization of $217.92 million, a price-to-earnings ratio of -2.91 and a beta of 0.79. Senseonics has a 52 week low of $0.32 and a 52 week high of $0.75. The firm has a 50-day simple moving average of $0.41 and a 200-day simple moving average of $0.45. The company has a quick ratio of 2.89, a current ratio of 3.11 and a debt-to-equity ratio of 59.17.

Senseonics (NYSE:SENS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $4.87 million during the quarter, compared to analysts’ expectations of $4.86 million. Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. On average, equities analysts predict that Senseonics will post -0.13 earnings per share for the current fiscal year.

Institutional Trading of Senseonics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Senseonics by 0.7% during the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after purchasing an additional 155,715 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Senseonics by 30.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after buying an additional 211,128 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after acquiring an additional 85,501 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after acquiring an additional 51,000 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Senseonics in the first quarter valued at $162,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.